ArticleVirchows Archiv : an international journal of pathology2017
High neuronatin (NNAT) expression is associated with poor outcome in breast cancer.
Article in Virchows Archiv : an international journal of pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- The prognostic importance of neuronatin positivity as immunohistochemical in patients with lung adenocarcinoma in the development of brain metastasis.Scientific reports · 2025Article
- Aging-associated alterations in gene regulatory networks associate with risk, prognosis and response to therapy in lung adenocarcinoma.npj aging · 2025Article
- Exploring tumor-normal cross-talk with TranNet: Role of the environment in tumor progression.PLoS computational biology · 2023Article
- Exploring tumor-normal cross-talk with TranNet: role of the environment in tumor progression.bioRxiv : the preprint server for biology · 2023Article
- Claudin 4 enhances the malignancy of glioma cells via NNAT/Wnt signaling.American journal of cancer research · 2023Article
- Spontaneous and ART-induced large offspring syndrome: similarities and differences in DNA methylome.Epigenetics · 2022Article
- Epigenome-wide scan identifies differentially methylated regions for lung cancer using pre-diagnostic peripheral blood.Epigenetics · 2022Article
- In Silico Identification of Key Genes and Immune Infiltration Characteristics in Epicardial Adipose Tissue from Patients with Coronary Artery Disease.BioMed research international · 2022Article
- Integrated genomics point to immune vulnerabilities in pleural mesothelioma.Scientific reports · 2021Observational
- The predictive potential of Neuronatin for neoadjuvant chemotherapy of breast cancer.Cancer biomarkers : section A of Disease markers · 2021Article
- Identification of Tumor Microenvironment-Related Prognostic Genes in Sarcoma.Frontiers in genetics · 2021Article
- Genetic and microenvironmental differences in non-smoking lung adenocarcinoma patients compared with smoking patients.Translational lung cancer research · 2020Article
- G-Protein-Coupled Estrogen Receptor (GPER)-Specific Agonist G1 Induces ER Stress Leading to Cell Death in MCF-7 Cells.Biomolecules · 2019Article
- Multi-view based integrative analysis of gene expression data for identifying biomarkers.Scientific reports · 2019Article
- Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome.Breast cancer research and treatment · 2019Article
- Proteomic Advances in Glial Tumors through Mass Spectrometry Approaches.Medicina (Kaunas, Lithuania) · 2019Review
- The role of PEG3 in the occurrence and prognosis of colon cancer.OncoTargets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuronatin (NNAT) is a proteolipid involved in cation homeostasis especially in the developing brain. Its expression has been associated with the progression of lung cancer, glioblastoma, and neuroblastoma as well as glucose induced apoptosis in pancreatic cells. We performed a retrospective study of 148 breast cancer specimens for NNAT expression by immunohistochemistry to evaluate this protein as a prognostic marker for breast cancer. We found a high NNAT immunoreactivity score (by multivariate cox regression) to be an independent prognostic marker for relapse-free (hazard ratio HR = 3.55, p = 0.002) and overall survival (HR = 6.29, p < 0.001). However, NNAT expression was not associated with classical parameters such as hormone receptor expression (p = 0.86) or lymph node metastasis (p = 0.83). Additional independent risk factors in this study population were tumor size (≤2 cm; overall survival: HR = 0.36, p = 0.023; relapse-free survival: HR = 0.26, p < 0.01) and blood vessel infiltration (overall survival: HR = 0.34 p < 0.01). NNAT expression determined by immunohistochemistry might therefore become a helpful additional biomarker to identify high-risk breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.